Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation
出版年份 2022 全文链接
标题
Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical approaches to attenuate reactive metabolite formation
作者
关键词
-
出版物
BIOCHEMICAL PHARMACOLOGY
Volume -, Issue -, Pages 115336
出版商
Elsevier BV
发表日期
2022-11-02
DOI
10.1016/j.bcp.2022.115336
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminate in Mechanism-Based Inactivation of Cytochrome P450 3A
- (2022) Lloyd Wei Tat Tang et al. DRUG METABOLISM AND DISPOSITION
- Metabolic Activation of the Acrylamide Michael Acceptor Warhead in Futibatinib to an Epoxide Intermediate Engenders Covalent Inactivation of Cytochrome P450 3A
- (2022) Lloyd Wei Tat Tang et al. DRUG METABOLISM AND DISPOSITION
- The Ascension of Targeted Covalent Inhibitors
- (2022) Juswinder Singh JOURNAL OF MEDICINAL CHEMISTRY
- Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance
- (2022) Lloyd Wei Tat Tang et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
- (2022) Lloyd Wei Tat Tang et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Site-directed deuteration of dronedarone preserves cytochrome P4502J2 activity and mitigates its cardiac adverse effects in canine arrhythmic hearts
- (2022) Aneesh V. Karkhanis et al. Acta Pharmaceutica Sinica B
- Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone
- (2021) Lloyd Wei Tat Tang et al. MOLECULAR PHARMACOLOGY
- An exploratory analysis of effects of poyendarone, a deuterated analogue of dronedarone, on the canine model of paroxysmal atrial fibrillation
- (2021) Ryuichi Kambayashi et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib
- (2021) Lloyd Wei Tat Tang et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4
- (2021) Lloyd Wei Tat Tang et al. DRUG METABOLISM AND DISPOSITION
- Infigratinib: First Approval
- (2021) Connie Kang DRUGS
- Evaluation of drug-drug interactions of pemigatinib in healthy participants
- (2021) Tao Ji et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
- (2021) Liangxing Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5
- (2021) Lloyd Wei Tat Tang et al. MOLECULAR PHARMACOLOGY
- How the Deuteration of Dronedarone Can Modify Its Cardiovascular Profile: In Vivo Characterization of Electropharmacological Effects of Poyendarone, a Deuterated Analogue of Dronedarone
- (2020) Ryuichi Kambayashi et al. Cardiovascular Toxicology
- FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
- (2020) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
- (2020) Phillip C. C. Liu et al. PLoS One
- Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class
- (2020) April Weaver et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Erdafitinib: First Global Approval
- (2019) Anthony Markham DRUGS
- Resistance Mechanisms to Targeted Therapies inROS1+andALK+Non–small Cell Lung Cancer
- (2018) Caroline E. McCoach et al. CLINICAL CANCER RESEARCH
- Dronedarone-Induced Cardiac Mitochondrial Dysfunction and Its Mitigation by Epoxyeicosatrienoic Acids
- (2018) Aneesh Karkhanis et al. TOXICOLOGICAL SCIENCES
- Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease
- (2018) Marissa Dean et al. Drug Design Development and Therapy
- A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor
- (2018) Ciara M. Kelly et al. INVESTIGATIONAL NEW DRUGS
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
- (2017) Timothy P.S. Perera et al. MOLECULAR CANCER THERAPEUTICS
- Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites
- (2016) Aneesh Karkhanis et al. BIOCHEMICAL PHARMACOLOGY
- Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
- (2015) Padmanee Sharma et al. CELL
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib
- (2015) Han Kiat Ho et al. DRUG METABOLISM REVIEWS
- Mechanisms of drug-induced liver injury
- (2014) Camilla Stephens et al. Current Opinion in Allergy and Clinical Immunology
- Drug resistance to targeted therapies: Déjà vu all over again
- (2014) Floris H. Groenendijk et al. Molecular Oncology
- Using Deuterium in Drug Discovery: Leaving the Label in the Drug
- (2013) Thomas G. Gant JOURNAL OF MEDICINAL CHEMISTRY
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
- (2013) Ulrich M. Zanger et al. PHARMACOLOGY & THERAPEUTICS
- Deuterated Clopidogrel Analogues as a New Generation of Antiplatelet Agents
- (2013) Yaoqiu Zhu et al. ACS Medicinal Chemistry Letters
- Enhanced Plasma Concentration by Selective Deuteration of Rofecoxib in Rats
- (2012) Frank Schneider et al. ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
- Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
- (2012) Caterina Carmi et al. BIOCHEMICAL PHARMACOLOGY
- Drug discovery for a new generation of covalent drugs
- (2012) Amit S Kalgutkar et al. Expert Opinion on Drug Discovery
- Drug safety evaluation of dronedarone in atrial fibrillation
- (2012) Gaetano M De Ferrari et al. Expert Opinion On Drug Safety
- Mechanism-Based Inactivation (MBI) of Cytochrome P450 Enzymes: Structure–Activity Relationships and Discovery Strategies To Mitigate Drug–Drug Interaction Risks
- (2012) Suvi T. M. Orr et al. JOURNAL OF MEDICINAL CHEMISTRY
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver injury caused by drugs: an update
- (2011) G Stirnimann et al. SWISS MEDICAL WEEKLY
- Mechanisms of Drug Toxicity and Relevance to Pharmaceutical Development
- (2010) F. Peter Guengerich Drug Metabolism and Pharmacokinetics
- Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages
- (2010) Shibashish Giri et al. Expert Opinion on Drug Metabolism & Toxicology
- Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment
- (2009) Dennis A. Smith et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?
- (2009) Amitâ S. Kalgutkar et al. CHEMISTRY & BIODIVERSITY
- Dronedarone
- (2009) Chinmay Patel et al. CIRCULATION
- A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout
- (2009) Ming-Han H Lee et al. DRUG SAFETY
- Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity
- (2009) Sudipta Saha et al. TOXICOLOGY LETTERS
- Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
- (2008) Ulrich M. Zanger et al. ANALYTICAL AND BIOANALYTICAL CHEMISTRY
- Cholangiocarcinoma
- (2008) Stefania Mosconi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Increased Mortality after Dronedarone Therapy for Severe Heart Failure
- (2008) Lars Køber et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now